Radiopharmaceutical publicly funded in some provinces has fewer side effects than chemotherapy and can increase survival by ...

Last year, nearly half a million cancer patients received life-saving treatments, from a medicine, that's active ingredient was created at Mizzou.

Forecasts show cancer's global footprint expanding sharply, with annual case counts expected to rise 20% by 2030 and swell by ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S.

The article continued: The number of annual cancer cases is expected to rise by 20% by 2030 and jump by 75% by 2050, ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump ...

This Saturday, the Purdue Institute for Cancer Research will host their annual 5K challenge event to raise money for cancer ...

On the heels of similar investment pledges from Eli Lilly and Johnson & Johnson, Switzerland’s Novartis is stepping up to the ...

The sector has seen billions in merger and acquisition activity in recent years; a September 2024 analysis by Insight ...